SPY342.73-0.65 -0.19%
DIA281.97-0.98 -0.35%
IXIC11,484.69-31.80 -0.28%

Bristol Myers Squibb Announces Phase 3 CheckMate -816 Trial Met A Primary Endpoint Of Pathologic Complete Response In Resectable Non-Small Cell Lung Cancer

CheckMate -816 met a primary endpoint of improved pathologic complete response in patients who received Opdivo plus chemotherapy before surgery Positive results mark the first time an immune checkpoint inhibitor-based

· 10/07/2020 07:00

CheckMate -816 met a primary endpoint of improved pathologic complete response in patients who received Opdivo plus chemotherapy before surgery

Positive results mark the first time an immune checkpoint inhibitor-based combination has demonstrated superior efficacy versus chemotherapy as neoadjuvant therapy in a Phase 3 trial in resectable non-small cell lung cancer

Opdivo-based treatments have now shown benefit in four Phase 3 clinical trials in early-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma